Affinage

MLKL

Mixed lineage kinase domain-like protein · UniProt Q8NB16

Length
471 aa
Mass
54.5 kDa
Annotated
2026-06-10
100 papers in source corpus 37 papers cited in narrative 36 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 8/8 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

MLKL is the terminal effector of necroptosis, a lytic programmed cell death pathway in which it is converted from a quiescent cytosolic pseudokinase into a membrane-disrupting executioner (PMID:24703947, PMID:24012422). Structurally, MLKL is a catalytically dead pseudokinase comprising an N-terminal four-helix bundle (4HB) death effector domain tethered through a brace helix to a C-terminal pseudokinase domain; RIPK3-mediated phosphorylation of the pseudoactive site (T357/S358 in human) is the licensing event, and mutations that disrupt the pseudoactive site or the brace region produce constitutive, RIPK3-independent killing, defining the brace and pseudokinase domain as the auto-inhibitory molecular switch (PMID:24703947, PMID:24012422, PMID:32561755). Activation proceeds through an ordered conformational cascade: phosphorylation drives pseudokinase-domain dimerization, the protein disengages from RIPK3, and a central coiled coil formed by the ~80 Å brace helix nucleates elongated homotetramers, releasing the 4HB domain for membrane engagement (PMID:33850121, PMID:34158471, PMID:37884510). Highly phosphorylated inositol phosphates generated by IPMK and ITPK1 displace the auto-inhibitory brace to permit oligomerization and membrane localization, providing metabolite-level control over the switch (PMID:29883610). The liberated 4HB binds phosphoinositides and cardiolipin and permeabilizes membranes, functioning as a conserved cation channel and assembling into SDS-resistant, disulfide-dependent amyloid-like polymers that are required for killing and are blocked by cysteine-targeting probes such as necrosulfonamide (PMID:24703947, PMID:27033670, PMID:28827318, PMID:26868910). Activated MLKL is trafficked from cytoplasmic necrosomes to the plasma membrane via Golgi–microtubule–actin routes and accumulates as membrane hotspots, a step further tuned by ESCRT-III-mediated membrane shedding, multi-mono-ubiquitylation, ITCH-dependent K63 ubiquitylation that diverts MLKL to endosomes, TAM-kinase Tyr376 phosphorylation that promotes oligomerization, and HSP70-facilitated polymerization (PMID:28388412, PMID:31230815, PMID:32561730, PMID:34698396, PMID:34999730, PMID:32156734). Beyond plasma membrane rupture, MLKL drives inflammatory and organelle-directed outputs including NLRP3 inflammasome activation via potassium efflux, lysosomal membrane permeabilization and cathepsin B release, and mitochondrial DNA release that triggers cGAS-STING/IFN-β signaling (PMID:28096356, PMID:28130493, PMID:37996483, PMID:40614706). MLKL additionally carries out RIPK3-independent functions: constitutive regulation of endosomal trafficking and extracellular vesicle generation, control of autophagic flux (suppressed by activated MLKL but promoted via CAMK2 phosphorylation under starvation), macrophage and Kupffer cell phagocytosis, Schwann cell myelin breakdown via S441 phosphorylation, and modulation of hepatic insulin signaling through PI(3,4,5)P3 production (PMID:28666573, PMID:30344099, PMID:32220583, PMID:34282994, PMID:35689613, PMID:30837196).

Mechanistic history

Synthesis pass · year-by-year structured walk · 16 steps
  1. 2013 High

    Establishing why a kinase-fold protein with no catalytic activity is required for necroptosis defined MLKL as a phosphorylation-gated molecular switch rather than an enzyme.

    Evidence Crystal structure of MLKL plus MLKL-deficient mice and structure-guided pseudoactive-site mutagenesis in TNF-induced necroptosis rescue

    PMID:24012422

    Open questions at the time
    • Did not resolve how phosphorylation is transduced into membrane disruption
    • Downstream membrane target not yet defined
  2. 2013 Medium

    Placing MLKL genetically downstream of RIP3 in TLR3/TRIF-driven necrosis established MLKL as an obligate effector in a defined necroptosis axis independent of RIP1.

    Evidence Genetic epistasis with MLKL knockdown/deficiency and RIP3 kinase inhibitors in cell death assays

    PMID:24019532

    Open questions at the time
    • Single lab
    • Did not address direct biochemical interaction
  3. 2014 High

    Identifying the RIPK3 phosphorylation sites and showing phospho-MLKL oligomerizes, binds phosphoinositides/cardiolipin, and disrupts membranes directly linked the switch to its killing mechanism.

    Evidence In vitro kinase assay, phospho-specific antibody, lipid binding, fractionation, and live-cell imaging

    PMID:24703947

    Open questions at the time
    • Did not resolve the structural basis of oligomerization
    • Mechanism of trafficking to plasma membrane unaddressed
  4. 2016 High

    Defining how MLKL kills addressed whether membrane disruption is channel-based, showing the 4HB domain forms a cation channel and is a conserved, transferable permeabilizing module.

    Evidence Patch-clamp electrophysiology with SCAM topology mapping, ion selectivity assays, and cross-species recombinant 4HB liposome permeabilization

    PMID:26868910 PMID:27033670

    Open questions at the time
    • Channel versus pore versus polymer contribution to lysis not fully reconciled
    • Stoichiometry of the membrane-active species unresolved
  5. 2017 High

    Resolving the physical nature of membrane-active MLKL showed it forms amyloid-like polymers required for killing, and that membrane rupture is actively delayed by ESCRT-III shedding and coupled to NLRP3 inflammasome activation.

    Evidence Recombinant 4HB amyloid assays with EM/Congo red and necrosulfonamide conjugation; live-cell Ca2+/PS imaging with ESCRT-III knockouts; domain mapping with NLRP3/caspase-1/GSDMD knockouts and K+ efflux measurement

    PMID:28096356 PMID:28130493 PMID:28388412 PMID:28827318

    Open questions at the time
    • Relationship between amyloid polymers and ion channel activity unsettled
    • How ESCRT-III is recruited to activated MLKL not defined
  6. 2017 Medium

    Discovering constitutive MLKL association with endosomes revealed a RIPK3-independent role in endocytic trafficking and extracellular vesicle release distinct from killing.

    Evidence Co-IP with ESCRT proteins and flotillins, endosomal fractionation, and EV isolation in MLKL-deficient cells

    PMID:28666573

    Open questions at the time
    • Single lab
    • Molecular determinant of constitutive endosome targeting unknown
  7. 2018 High

    Identifying inositol phosphate kinases as essential for MLKL activation established metabolite-level control of the switch by brace displacement.

    Evidence CRISPR genetic screen, IP-kinase KO rescue, oligomerization/membrane assays, and in vitro brace-displacement assay

    PMID:29883610

    Open questions at the time
    • Which specific IP species acts in vivo not fully pinned down
    • Spatial site of IP action unresolved
  8. 2018 Medium

    Mapping cell-type-specific and subcellular regulation extended MLKL biology to nuclear shuttling, neutrophil NET formation, and Schwann cell myelin breakdown via a non-RIPK3 S441 site.

    Evidence Nuclear export inhibition with fractionation; RIPK3/MLKL/PAD4 KO with NET quantification; Schwann-cell-specific conditional KO with S441 phospho-mapping

    PMID:30181240 PMID:30271893 PMID:30344099

    Open questions at the time
    • S441 kinase identity not established
    • Generality of nuclear shuttling across cell types unclear
  9. 2019 Medium

    Defining additional input modifications and non-lethal outputs showed TAM kinases phosphorylate Tyr376 to drive oligomerization, BRD4/IRF1/P-TEFb controls MLKL transcription, MLKL restricts intracellular Listeria, and a viral mimic sequesters RIPK3.

    Evidence TAM KO/inhibitors with phospho-Tyr376 detection and SIRS model; ChIP/Co-IP of the transcription complex with BET inhibitors; Listeria binding and Ripk3-/- dissemination; viral MLKL-like Co-IP and rescue

    PMID:30644439 PMID:30975711 PMID:31230815 PMID:31553902

    Open questions at the time
    • Integration of Tyr376 with T357/S358 phosphorylation not fully ordered
    • Mechanism of direct bacterial restriction unresolved
  10. 2019 Medium

    Linking MLKL membrane association to autophagy and insulin signaling revealed RIPK3-independent metabolic functions.

    Evidence LC3B lipidation/flux assays in MLKL KO cells with intracellular membrane correlation; MLKL KO mice with hepatocyte PI(3,4,5)P3 assays

    PMID:30709919 PMID:30837196

    Open questions at the time
    • Direct molecular target on autophagic membranes unknown
    • How MLKL modulates PIP3 production mechanistically undefined
  11. 2020 High

    Visualizing endogenous MLKL trafficking and identifying the brace D139V switch mutation and HSP70 chaperone established trafficking checkpoints and protein-folding control of the activation pathway.

    Evidence Single-cell live/super-resolution imaging with Golgi/microtubule/actin disruption; MlklD139V knock-in mice; biotin-NBC1 pulldown and in vitro HSP70–MLKL-NTD polymerization assays

    PMID:32156734 PMID:32561730 PMID:32561755

    Open questions at the time
    • Cargo/motor machinery directing MLKL trafficking not fully identified
    • How HSP70 selects the MLKL polymerization client unresolved
  12. 2020 Medium

    Distinguishing two opposing MLKL effects on autophagy showed RIPK3-driven MLKL suppresses autophagic flux whereas CAMK2-phosphorylated MLKL promotes it under starvation.

    Evidence LC3 flux reporters with MLKL/RIP3 KO hepatocytes and overexpression; CAMK2 inhibition/siRNA with pHluorin-LC3 reporter and Co-IP

    PMID:32220583 PMID:34282994

    Open questions at the time
    • CAMK2 phosphorylation site on MLKL not mapped
    • How a single protein produces opposite autophagy outcomes mechanistically unclear
  13. 2021 High

    Structural and ubiquitin-based studies refined the activation cascade as ordered conformational interconversion and coiled-coil oligomerization, and defined ubiquitylation as a brake on activated MLKL.

    Evidence Crystal structures with conformation-specific Monobodies; human MLKL pseudokinase crystal structure with dimer-interface/coiled-coil mutagenesis; MLKL-DUB fusion, ubiquitin-site MS, and proteasome/lysosome inhibitors

    PMID:33850121 PMID:34158471 PMID:34698396

    Open questions at the time
    • Temporal coordination of conformational change with trafficking not fully resolved
    • E3 ligases for the multi-mono-ubiquitylation not all identified
  14. 2021 Medium

    Expanding the regulatory and signaling network placed MLKL upstream of CaMKII in smooth muscle necroptosis and identified ITCH-driven K63 ubiquitylation as an endosomal sorting signal.

    Evidence siRNA epistasis with phosphorylation/oligomerization readouts; site-specific K63 ubiquitin MS, ITCH Co-IP, MLKL lysine mutants, and bacterial trafficking assays

    PMID:34572045 PMID:34999730

    Open questions at the time
    • Single-lab pathway-order claims
    • How K63 ubiquitylation competes with plasma-membrane trafficking quantitatively unclear
  15. 2023 High

    Higher-resolution oligomer structures and organelle-directed studies established homotetramerization as the prerequisite for 4HB release and extended MLKL targets to lysosomes, Skp2-mediated turnover, and acinar CXCL10 secretion.

    Evidence Crystal structure with negative-stain EM and tetramerization mutants; MLKL-lysosome imaging with CTSB rescue; Skp2 Co-IP/ubiquitination with cisplatin sensitivity; Mlkl-/- versus Ripk3-/- AP model with CXCL10 neutralization

    PMID:36828808 PMID:37532777 PMID:37884510 PMID:37996483

    Open questions at the time
    • Structure of the membrane-inserted oligomer still lacking
    • How non-lethal MLKL activity drives chemokine secretion mechanistically undefined
  16. 2025 High

    Connecting MLKL to mitochondrial DNA release closed a gap on how necroptosis triggers cell-autonomous inflammation via cGAS-STING/IFN-β.

    Evidence MLKL-mitochondria co-localization, mtDNA release assay, cGAS-STING/IFN-β readouts, microtubule disruption, and an in vivo IBD model with STING interference

    PMID:40614706

    Open questions at the time
    • How MLKL permeabilizes mitochondrial membranes for mtDNA egress not resolved
    • Relative contribution versus other necroptotic inflammatory outputs unclear

Open questions

Synthesis pass · forward-looking unresolved questions
  • How the conformationally activated, oligomeric MLKL species is structurally arranged within target membranes, and how trafficking and ubiquitin codes route it to plasma membrane versus endosomes, lysosomes, and mitochondria for distinct lethal and non-lethal outcomes, remains unresolved.
  • No structure of the membrane-embedded MLKL oligomer
  • Kinases for several non-RIPK3 sites (S441, CAMK2 site) and their integration not defined
  • Determinants selecting among competing organelle destinations not established

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0005198 structural molecule activity 3 GO:0008289 lipid binding 2 GO:0005215 transporter activity 1 GO:0140657 ATP-dependent activity 1
Localization
GO:0005886 plasma membrane 4 GO:0005739 mitochondrion 2 GO:0005764 lysosome 2 GO:0005768 endosome 2 GO:0005829 cytosol 2 GO:0005634 nucleus 1
Pathway
R-HSA-168256 Immune System 3 R-HSA-5357801 Programmed Cell Death 3 R-HSA-9609507 Protein localization 3 R-HSA-9612973 Autophagy 3
Complex memberships
necrosome (RIPK3-MLKL)

Evidence

Reading pass · 36 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2014 RIPK3 phosphorylates MLKL at T357 and S358; phosphorylated MLKL forms oligomers that bind phosphatidylinositol lipids and cardiolipin, enabling translocation from cytosol to plasma and intracellular membranes where it directly disrupts membrane integrity to cause necrotic cell death. In vitro phosphorylation assay, phospho-specific monoclonal antibody, lipid-binding assay, cell fractionation, live-cell imaging Molecular cell High 24703947
2013 MLKL is a pseudokinase (catalytically inactive) that binds ATP but has no enzymatic activity; it comprises a four-helical bundle (4HB) domain tethered to a pseudokinase domain; RIPK3-mediated phosphorylation of the pseudoactive site is essential for necroptotic signaling; structure-guided mutation of the pseudoactive site causes constitutive, RIPK3-independent necroptosis, demonstrating a molecular switch mechanism. Crystal structure of MLKL, MLKL-deficient mouse generation, TNF-induced necroptosis rescue assay, structure-guided mutagenesis Immunity High 24012422
2013 MLKL acts downstream of RIP3 kinase in TLR3/TRIF-driven programmed necrosis, independently of RIP1, placing MLKL as a required effector in the TRIF-RIP3-MLKL necroptosis axis. Genetic epistasis (MLKL knockdown/deficiency), RIP3 kinase inhibitors, cell death assays The Journal of biological chemistry Medium 24019532
2016 MLKL forms cation channels permeable preferentially to Mg2+ over Ca2+ in the presence of Na+ and K+; the N-terminal domain (helices H1–H6) is sufficient for channel formation; helices H1, H2, H3, H5, and H6 are transmembrane segments while H4 is cytoplasmic; MLKL-induced membrane depolarization and cell death correlate with channel activity. Electrophysiology (patch-clamp), substituted cysteine accessibility method (SCAM), ion selectivity assays, cell death assays Cell research High 27033670
2017 MLKL forms SDS-resistant, disulfide bond-dependent amyloid-like polymers during necroptosis; recombinant MLKL N-terminal domain forms amyloid-like fibers (~5 nm diameter) that bind Congo red; MLKL mutants unable to polymerize fail to induce necroptosis; necrosulfonamide conjugates cysteine 86 of human MLKL, blocking polymer formation and cell death. SDS-PAGE, proteinase K resistance assay, electron microscopy, Congo red binding, site-directed mutagenesis, chemical probe (necrosulfonamide) conjugation Proceedings of the National Academy of Sciences of the United States of America High 28827318
2017 During necroptosis, MLKL-dependent Ca2+ influx and phosphatidylserine exposure on the outer plasma membrane leaflet precede membrane rupture; ESCRT-III machinery is recruited downstream of MLKL activation to form PS-exposing membrane 'bubbles' released from the cell surface, acting to delay/limit plasma membrane disruption and modulate necroptotic kinetics. Live-cell imaging (Ca2+ and PS reporters), flow cytometry, ESCRT-III genetic knockdown/knockout, cell death assays Cell High 28388412
2017 MLKL associates with endosomes independently of RIPK3 (constitutive function) and controls endocytosed protein transport, receptor/ligand degradation, and extracellular vesicle generation; upon RIPK3 activation, enhanced MLKL–endosome association leads to MLKL binding to ESCRT proteins and flotillins and its release within extracellular vesicles. Co-immunoprecipitation with ESCRT proteins and flotillins, endosomal fractionation, extracellular vesicle isolation, MLKL-deficient cell comparison Immunity Medium 28666573
2017 MLKL-induced NLRP3 inflammasome activation requires (i) the death effector four-helical bundle of MLKL, (ii) MLKL oligomerization and membrane association, and (iii) intracellular potassium efflux; this occurs cell-intrinsically before cell lysis; GSDMD is not required for MLKL-dependent IL-1β secretion during necroptosis. Domain deletion/mutation analysis, K+ efflux measurement, ASC speck imaging, NLRP3/caspase-1 genetic KO, GSDMD KO Proceedings of the National Academy of Sciences of the United States of America High 28096356 28130493
2018 Inositol phosphate (IP) kinases IPMK and ITPK1 are essential for MLKL-dependent necroptosis; in IP kinase mutant cells, MLKL fails to oligomerize and localize to membranes despite proper RIPK3-mediated phosphorylation; highly phosphorylated IP products (not lowly phosphorylated precursors) displace the MLKL auto-inhibitory brace region, identifying metabolite control of MLKL activation. Genetic screen in human cells (CRISPR), IP kinase KO rescue, oligomerization assay, membrane localization assay, in vitro brace-displacement assay Molecular cell High 29883610
2018 RIPK3 and MLKL continuously shuttle between nucleus and cytoplasm; during TNF-induced necroptosis, nuclear MLKL becomes phosphorylated and oligomerized; pharmacological inhibition of nuclear export retains RIPK3/MLKL in the nucleus, prevents cytosolic RIPK3/MLKL oligomerization, and reduces necroptotic cell death, indicating nuclear passage as a regulatory step for necrosome formation. Nuclear export inhibitor (leptomycin B), subcellular fractionation, immunofluorescence, cell death assays Communications biology Medium 30271893
2018 MLKL activates PAD4-dependent NET formation in necroptotic neutrophils: MLKL translocates from cytoplasm to plasma membrane and stimulates downstream NADPH oxidase-independent ROS production, nuclear membrane breakdown, chromatin decondensation, histone hypercitrullination, and NET extrusion; PAD4 acts downstream of RIPK1/RIPK3/MLKL. Genetic KO of RIPK3 and MLKL, MLKL translocation imaging, ROS assay, PAD4 KO rescue, NET quantification Science signaling Medium 30181240
2018 During peripheral nerve injury, MLKL is phosphorylated at serine 441 (not by RIP3) and targets the myelin sheath membrane of Schwann cells to promote myelin breakdown; Schwann cell-specific MLKL knockout delays myelin breakdown and reduces nerve regeneration; MLKL overexpression accelerates myelin breakdown. Schwann cell-specific conditional KO, MLKL overexpression, phospho-site mapping, myelin breakdown assay, axon regeneration assay Molecular cell High 30344099
2019 TAM receptor tyrosine kinases (Tyro3, Axl, Mer) phosphorylate MLKL at Tyr376, promoting MLKL oligomerization (but not membrane translocation or RIPK3-mediated phosphorylation); pharmacological or genetic TAM inhibition potently inhibits necroptotic death and protects mice from systemic inflammatory response syndrome. TAM kinase inhibitors, TAM KO cells, phospho-Tyr376 MLKL detection, oligomerization assay, in vivo SIRS model Molecular cell High 31230815
2019 MLKL directly binds to intracellular Listeria monocytogenes in the cytosol and inhibits their replication independently of host cell killing; RIPK3-MLKL pathway activation by Listeria leads to phospho-MLKL that does not cause cell death but suppresses bacterial replication. MLKL direct binding to bacteria (co-localization/pulldown), RIPK3/MLKL KO infection assay, in vivo Listeria dissemination in Ripk3-/- mice The Journal of cell biology Medium 30975711
2020 Phosphorylated MLKL assembles into higher-order species at cytoplasmic necrosomes, then co-traffics with tight junction proteins to the cell periphery via Golgi-microtubule-actin-dependent mechanisms, and accumulates as micron-sized hotspots at the plasma membrane; this trafficking and plasma membrane accumulation are key checkpoints controlling necroptosis kinetics and threshold. Single-cell live imaging of endogenous MLKL, super-resolution microscopy, Golgi/microtubule/actin disruption, tight junction co-localization Nature communications High 32561730
2020 MLKL regulates autophagic flux independently of RIPK3: MLKL translocates first to autophagosomes then to the plasma membrane upon palmitic acid treatment; MLKL deficiency (but not RIP3 deficiency) prevents autophagosome–lysosome fusion inhibition; MLKL overexpression blocks autophagy independently of stimulus. mRFP-GFP-LC3 reporter (autophagy flux assay), MLKL/RIP3 KO hepatocytes, MLKL overexpression, LC3-II/p62 Western blot Journal of hepatology Medium 32220583
2020 A missense mutation in the MLKL brace region (D139V) confers constitutive, RIPK3-independent killing activity, demonstrating that the brace helix connecting the 4HB and pseudokinase domains is a critical regulatory element controlling MLKL auto-inhibition in vivo. Mouse knock-in model (MlklD139V), cell death assays in RIPK3-deficient background, histopathological analysis Nature communications High 32561755
2021 Conformational interconversion of the MLKL pseudokinase domain occurs upon activation: after RIPK3-mediated phosphorylation, MLKL undergoes a large conformational change and disengages from RIPK3; crystal structures of the pseudokinase domain with Monobody-27 (binding the RIPK3-interface epitope only after disengagement) and Monobody-32 (constitutive brace-region binding) define two distinct pseudokinase conformations as key regulatory steps. Crystal structures of MLKL pseudokinase domain in complex with Monobodies, intracellular Monobody expression, necroptosis assays Nature communications High 33850121
2021 Necroptosis-specific multi-mono-ubiquitylation of MLKL occurs after its activation and oligomerization; ubiquitylated MLKL accumulates at organellar/plasma membranes; ubiquitylation drives proteasome- and lysosome-dependent MLKL turnover; constitutive deubiquitylation of MLKL (via MLKL-DUB fusion) licenses MLKL auto-activation independent of necroptosis signaling, showing ubiquitylation restrains basal activated MLKL levels. MLKL-DUB fusion strategy, plasma membrane-targeted DUB expression, ubiquitin site mapping (MS), digitonin fractionation, proteasome/lysosome inhibitors The EMBO journal High 34698396
2021 CAMK2/CaMKII phosphorylates MLKL in response to serum and amino acid starvation independently of RIPK3, promoting autophagic flux (autophagosome–lysosome fusion) and protecting cells from starvation-induced death; this is mechanistically distinct from the necroptotic RIPK3-MLKL pathway, which instead suppresses autophagic flux. CAMK2 inhibitor/siRNA, MLKL KO/siRNA, LC3 flux reporter (pHluorin-mKate2-LC3), co-immunoprecipitation Autophagy Medium 34282994
2021 K63-linked polyubiquitin chains conjugated by the E3 ligase ITCH to distinct lysine residues in the MLKL N-terminal HeLo domain of phosphorylated MLKL redirect MLKL to endosomes (instead of plasma membrane), resulting in its release within extracellular vesicles and enhanced endosomal trafficking of intracellular bacteria to lysosomes. Site-specific ubiquitin chain characterization (MS), ITCH Co-IP/WW-domain interaction, MLKL lysine mutants, endosomal fractionation, bacterial trafficking assay Cell death and differentiation Medium 34999730
2019 RIPK3-mediated phosphorylation of the MLKL pseudokinase domain drives pseudokinase domain dimerization as the initial oligomerization step; subsequent internal coiled-coil self-assembly forms the full MLKL oligomer; crystal structure of human MLKL reveals two inter-dimer interfaces; mutations destroying both interfaces prevent RIPK3-induced oligomerization and necroptosis; coiled-coil disruption prevents oligomerization but not dimerization. Crystal structure of human MLKL pseudokinase domain, site-directed mutagenesis of dimer interfaces and coiled-coil, necroptosis assays Cell death & disease High 34158471
2023 RIPK3-mediated phosphorylation of the human MLKL activation loop drives pseudokinase domain dimerization, which nucleates elongated homotetramers via a central coiled coil formed by the ~80 Å brace helix; tetramerization is an essential prerequisite for release and reorganization of four-helix bundle domains for membrane permeabilization. Crystal structure, negative-stain electron microscopy, MLKL tetramerization-defective mutants, cell death assays Nature communications High 37884510
2020 Hsp70 performs dual roles in necroptosis: it stabilizes MLKL protein under basal conditions (client protein function) and promotes MLKL N-terminal domain polymerization through its substrate-binding domain (SBD) during necroptosis; NBC1 covalently conjugates C574 and C603 of the Hsp70 SBD to block MLKL polymerization and cell death; SBD mutations at both cysteines abolish this pro-polymerization function. Biotin-NBC1 pulldown identifying Hsp70, in vitro Hsp70–MLKL-NTD interaction/polymerization assay, SBD mutagenesis, Hsp70 knockdown Proceedings of the National Academy of Sciences of the United States of America High 32156734
2023 Activated MLKL translocates to the lysosomal membrane during necroptosis; MLKL polymerization induces lysosome clustering, fusion, and lysosomal membrane permeabilization (LMP), releasing cathepsin B (CTSB) into the cytosol; CTSB contributes to cell death downstream of MLKL, as CTSB inhibition or knockdown protects cells from necroptosis. MLKL-lysosome co-localization imaging, LMP assay, cathepsin activity measurement, CTSB inhibitor/siRNA rescue Cell death and differentiation Medium 37996483
2025 Phospho-MLKL translocates to mitochondria and induces microtubule-dependent release of mitochondrial DNA (mtDNA) into the cytosol, which activates the cGAS-STING pathway to upregulate IFN-β expression; this represents a cell-autonomous inflammatory signaling mechanism downstream of MLKL activation. MLKL-mitochondria co-localization, mtDNA release assay, cGAS-STING pathway readout (IFN-β), microtubule disruption, in vivo IBD model with STING pathway interference Molecular cell High 40614706
2019 Poxviral MLKL-like proteins function as dominant-negative mimics of host MLKL by sequestering RIPK3 via its kinase domain, thereby preventing MLKL engagement and phosphorylation and blocking necroptotic cell death. Expression of viral MLKL-like proteins in human and mouse cells, Co-IP with RIPK3, MLKL phosphorylation assay, cell death rescue assay Cell reports Medium 31553902
2016 The MLKL 4HB (four-helix bundle) domain mediates membrane permeabilization and is evolutionarily conserved in this function across species; forced dimerization of the human MLKL 4HB domain overcomes a species-specific defect and triggers cell death; recombinant 4HB proteins from mouse, frog, human, and chicken all permeabilize liposomes, most effectively those mimicking plasma membrane composition. Recombinant protein liposome permeabilization assay, forced dimerization, cross-species domain expression, cell death assays Cell death and differentiation High 26868910
2019 Activated MLKL attenuates autophagic flux by inhibiting autophagosome and/or autolysosome function upon translocation to intracellular membranes; this effect requires MLKL association with intracellular membranes and occurs independently of plasma membrane disruption. LC3B lipidation Western blot, autophagy flux assay, MLKL KO mouse dermal fibroblasts and HT-29 cells, MLKL intracellular membrane association Journal of cell science Medium 30709919
2023 The E3 ligase Skp2 interacts with MLKL and promotes its ubiquitination-mediated proteasomal degradation in cisplatin-resistant NSCLC cells; Skp2 knockdown restores MLKL levels and sensitizes resistant cells to cisplatin. Co-immunoprecipitation (Skp2–MLKL), ubiquitination assay, Skp2 knockdown/OE, cisplatin sensitivity rescue Communications biology Medium 37532777
2019 BRD4 forms a transcription complex with IRF1, P-TEFb, and RNA polymerase II to positively regulate MLKL transcription; BET inhibitors (JQ-1) downregulate MLKL expression by disrupting this complex, thereby inhibiting necroptosis. ChIP, Co-IP of transcription complex, BET inhibitor treatment, MLKL expression assay, cell death assays Cell death and differentiation Medium 30644439
2022 In macrophages, LPS-induced MLKL phosphorylation and oligomerization drives translocation to intracellular phagosomes and lysosomes (not plasma membrane), and this MLKL activity is required for macrophage phagocytic capability; MLKL-deficient Kupffer cells phagocytose fewer bioparticles in vivo. Bone marrow transplant (myeloid vs. non-myeloid Mlkl-/-), phagocytosis assay, MLKL subcellular fractionation/immunofluorescence, in vivo bioparticle phagocytosis Hepatology (Baltimore, Md.) Medium 35689613
2021 MLKL modulates insulin-stimulated PI(3,4,5)P3 production in liver cells, regulating hepatic insulin sensitivity independently of inflammation and independently of its canonical necroptosis-inducing function. MLKL KO mice (whole-body), in vitro hepatocyte insulin signaling (PI(3,4,5)P3 assay), inflammatory gene expression analysis (negative for inflammatory mechanism) Molecular metabolism Medium 30837196
2022 TGFβ induces translocation of RIPK3 and MLKL to mitochondria, causing mitochondrial dysfunction and ROS production; mitochondrial ROS activates CaMKII, which phosphorylates Smad2/3 to drive extracellular matrix production; MLKL deficiency prevents this signaling axis and reduces kidney fibrosis. RIPK3/MLKL mitochondrial fractionation, ROS measurement, CaMKII phosphorylation, Smad2/3 phosphorylation, MLKL KO in CKD model Matrix biology : journal of the International Society for Matrix Biology Medium 35964866
2021 MLKL activates downstream CaMKII in smooth muscle cells (SMCs) during RIPK3-mediated necroptosis; MLKL knockdown reduces CaMKII phosphorylation, whereas CaMKII knockdown does not affect MLKL phosphorylation, oligomerization, or trafficking, placing MLKL upstream of CaMKII in this pathway. siRNA knockdown of MLKL and CaMKII, phosphorylation Western blot, MLKL oligomerization assay, cell death assay Cells Medium 34572045
2023 MLKL activity in pancreatic acinar cells controls CXCL10 secretion independently of RIPK3 and cell death; CXCL10 then drives macrophage M1 polarization; MLKL KO reduces M1 polarization and AP severity. Mlkl-/- and Ripk3-/- mice in cerulein AP model, CXCL10 measurement, macrophage polarization assay, in vivo CXCL10 neutralization Cell death & disease Medium 36828808

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2014 Mixed lineage kinase domain-like protein MLKL causes necrotic membrane disruption upon phosphorylation by RIP3. Molecular cell 1338 24703947
2013 The pseudokinase MLKL mediates necroptosis via a molecular switch mechanism. Immunity 1046 24012422
2013 Toll-like receptor 3-mediated necrosis via TRIF, RIP3, and MLKL. The Journal of biological chemistry 814 24019532
2015 RIPK3 promotes cell death and NLRP3 inflammasome activation in the absence of MLKL. Nature communications 575 25693118
2017 ESCRT-III Acts Downstream of MLKL to Regulate Necroptotic Cell Death and Its Consequences. Cell 554 28388412
2014 RIPK1 regulates RIPK3-MLKL-driven systemic inflammation and emergency hematopoiesis. Cell 518 24813849
2017 Active MLKL triggers the NLRP3 inflammasome in a cell-intrinsic manner. Proceedings of the National Academy of Sciences of the United States of America 418 28096356
2017 MLKL, the Protein that Mediates Necroptosis, Also Regulates Endosomal Trafficking and Extracellular Vesicle Generation. Immunity 323 28666573
2020 MLKL trafficking and accumulation at the plasma membrane control the kinetics and threshold for necroptosis. Nature communications 288 32561730
2020 FADD and Caspase-8 Regulate Gut Homeostasis and Inflammation by Controlling MLKL- and GSDMD-Mediated Death of Intestinal Epithelial Cells. Immunity 234 32362323
2016 Cytotoxicity of crystals involves RIPK3-MLKL-mediated necroptosis. Nature communications 230 26817517
2017 MLKL Activation Triggers NLRP3-Mediated Processing and Release of IL-1β Independently of Gasdermin-D. Journal of immunology (Baltimore, Md. : 1950) 205 28130493
2015 PMA and crystal-induced neutrophil extracellular trap formation involves RIPK1-RIPK3-MLKL signaling. European journal of immunology 196 26531064
2016 MLKL forms cation channels. Cell research 174 27033670
2020 MLKL-dependent signaling regulates autophagic flux in a murine model of non-alcohol-associated fatty liver and steatohepatitis. Journal of hepatology 161 32220583
2021 ZBP1-MLKL necroptotic signaling potentiates radiation-induced antitumor immunity via intratumoral STING pathway activation. Science advances 160 34613770
2017 MLKL forms disulfide bond-dependent amyloid-like polymers to induce necroptosis. Proceedings of the National Academy of Sciences of the United States of America 151 28827318
2016 Necrosome core machinery: MLKL. Cellular and molecular life sciences : CMLS 147 27048809
2018 MLKL Requires the Inositol Phosphate Code to Execute Necroptosis. Molecular cell 146 29883610
2021 MLKL in cancer: more than a necroptosis regulator. Cell death and differentiation 145 33953348
2016 Contribution of RIP3 and MLKL to immunogenic cell death signaling in cancer chemotherapy. Oncoimmunology 144 27471616
2018 Nuclear RIPK3 and MLKL contribute to cytosolic necrosome formation and necroptosis. Communications biology 138 30271893
2018 RIPK3-MLKL-mediated necroinflammation contributes to AKI progression to CKD. Cell death & disease 122 30158627
2019 TAM Kinases Promote Necroptosis by Regulating Oligomerization of MLKL. Molecular cell 120 31230815
2021 MLKL: Functions beyond serving as the Executioner of Necroptosis. Theranostics 119 33754026
2019 Viral MLKL Homologs Subvert Necroptotic Cell Death by Sequestering Cellular RIPK3. Cell reports 106 31553902
2016 Evolutionary divergence of the necroptosis effector MLKL. Cell death and differentiation 106 26868910
2019 The pseudokinase MLKL regulates hepatic insulin sensitivity independently of inflammation. Molecular metabolism 91 30837196
2021 Conformational interconversion of MLKL and disengagement from RIPK3 precede cell death by necroptosis. Nature communications 89 33850121
2018 The pseudokinase MLKL activates PAD4-dependent NET formation in necroptotic neutrophils. Science signaling 85 30181240
2020 A missense mutation in the MLKL brace region promotes lethal neonatal inflammation and hematopoietic dysfunction. Nature communications 84 32561755
2018 Mixed Lineage Kinase Domain-like Protein MLKL Breaks Down Myelin following Nerve Injury. Molecular cell 80 30344099
2024 Gasdermin and MLKL necrotic cell death effectors: Signaling and diseases. Immunity 77 38479360
2020 The Killer Pseudokinase Mixed Lineage Kinase Domain-Like Protein (MLKL). Cold Spring Harbor perspectives in biology 75 31712266
2021 CAMK2/CaMKII activates MLKL in short-term starvation to facilitate autophagic flux. Autophagy 73 34282994
2019 RIP1/RIP3/MLKL mediates dopaminergic neuron necroptosis in a mouse model of Parkinson disease. Laboratory investigation; a journal of technical methods and pathology 73 31506635
2017 Insane in the membrane: a structural perspective of MLKL function in necroptosis. Immunology and cell biology 71 27999433
2021 Oligomerization-driven MLKL ubiquitylation antagonizes necroptosis. The EMBO journal 68 34698396
2023 MLKL polymerization-induced lysosomal membrane permeabilization promotes necroptosis. Cell death and differentiation 66 37996483
2019 Necroptosis mediators RIPK3 and MLKL suppress intracellular Listeria replication independently of host cell killing. The Journal of cell biology 63 30975711
2023 Dimethyl fumarate inhibits necroptosis and alleviates systemic inflammatory response syndrome by blocking the RIPK1-RIPK3-MLKL axis. Pharmacological research 62 36796462
2022 Loss of MLKL ameliorates liver fibrosis by inhibiting hepatocyte necroptosis and hepatic stellate cell activation. Theranostics 62 35836819
2021 A toolbox for imaging RIPK1, RIPK3, and MLKL in mouse and human cells. Cell death and differentiation 59 33589776
2020 Loss of MLKL (Mixed Lineage Kinase Domain-Like Protein) Decreases Necrotic Core but Increases Macrophage Lipid Accumulation in Atherosclerosis. Arteriosclerosis, thrombosis, and vascular biology 58 32212851
2019 Activated MLKL attenuates autophagy following its translocation to intracellular membranes. Journal of cell science 58 30709919
2022 Caspase-8 auto-cleavage regulates programmed cell death and collaborates with RIPK3/MLKL to prevent lymphopenia. Cell death and differentiation 56 35064213
2019 Ptpn6 inhibits caspase-8- and Ripk3/Mlkl-dependent inflammation. Nature immunology 52 31819256
2021 The molecular mechanisms of MLKL-dependent and MLKL-independent necrosis. Journal of molecular cell biology 51 33064829
2019 MLKL contributes to shikonin-induced glioma cell necroptosis via promotion of chromatinolysis. Cancer letters 50 31560934
2023 The Many Faces of MLKL, the Executor of Necroptosis. International journal of molecular sciences 48 37373257
2023 MLKL-Driven Inflammasome Activation and Caspase-8 Mediate Inflammatory Cell Death in Influenza A Virus Infection. mBio 47 36852999
2020 Necroptosis-blocking compound NBC1 targets heat shock protein 70 to inhibit MLKL polymerization and necroptosis. Proceedings of the National Academy of Sciences of the United States of America 46 32156734
2018 Interferons Transcriptionally Up-Regulate MLKL Expression in Cancer Cells. Neoplasia (New York, N.Y.) 46 30521981
2015 Post-translational control of RIPK3 and MLKL mediated necroptotic cell death. F1000Research 45 27158445
2023 Macrophage-derived MLKL in alcohol-associated liver disease: Regulation of phagocytosis. Hepatology (Baltimore, Md.) 43 35689613
2021 Surviving death: emerging concepts of RIPK3 and MLKL ubiquitination in the regulation of necroptosis. The FEBS journal 43 34710282
2023 Norovirus MLKL-like protein initiates cell death to induce viral egress. Nature 42 36991121
2016 MLKL inhibition attenuates hypoxia-ischemia induced neuronal damage in developing brain. Experimental neurology 42 26980487
2025 MLKL activates the cGAS-STING pathway by releasing mitochondrial DNA upon necroptosis induction. Molecular cell 40 40614706
2019 Combined Knockout of RIPK3 and MLKL Reveals Unexpected Outcome in Tissue Injury and Inflammation. Frontiers in cell and developmental biology 40 30842945
2023 MLKL deficiency alleviates neuroinflammation and motor deficits in the α-synuclein transgenic mouse model of Parkinson's disease. Molecular neurodegeneration 39 38041169
2021 Differential role of MLKL in alcohol-associated and non-alcohol-associated fatty liver diseases in mice and humans. JCI insight 37 33616081
2021 RIPK3 Activates MLKL-mediated Necroptosis and Inflammasome Signaling during Streptococcus Infection. American journal of respiratory cell and molecular biology 37 33625952
2023 RIPK3-MLKL necroptotic signalling amplifies STING pathway and exacerbates lethal sepsis. Clinical and translational medicine 36 37475188
2022 Site-specific ubiquitination of MLKL targets it to endosomes and targets Listeria and Yersinia to the lysosomes. Cell death and differentiation 36 34999730
2023 MLKL signaling regulates macrophage polarization in acute pancreatitis through CXCL10. Cell death & disease 35 36828808
2022 MLKL-mediated necroptosis is a target for cardiac protection in mouse models of type-1 diabetes. Cardiovascular diabetology 35 36030201
2024 Unveiling the interplay of MAPK/NF-κB/MLKL axis in brain health: Omega-3 as a promising candidates against copper neurotoxicity. Journal of environmental management 34 39357438
2020 RIP1/RIP3/MLKL-mediated necroptosis contributes to vinblastine-induced myocardial damage. Molecular and cellular biochemistry 34 33247805
2019 MLKL attenuates colon inflammation and colitis-tumorigenesis via suppression of inflammatory responses. Cancer letters 34 31158430
2018 Necroptosis: MLKL Polymerization. Journal of nature and science 34 30294675
2023 Phosphorylation-dependent pseudokinase domain dimerization drives full-length MLKL oligomerization. Nature communications 33 37884510
2021 The MLKL kinase-like domain dimerization is an indispensable step of mammalian MLKL activation in necroptosis signaling. Cell death & disease 33 34158471
2023 Necroptosis of macrophage is a key pathological feature in biliary atresia via GDCA/S1PR2/ZBP1/p-MLKL axis. Cell death & disease 32 36859525
2019 The bromodomain protein BRD4 positively regulates necroptosis via modulating MLKL expression. Cell death and differentiation 32 30644439
2023 Celastrol inhibits necroptosis by attenuating the RIPK1/RIPK3/MLKL pathway and confers protection against acute pancreatitis in mice. International immunopharmacology 28 37012867
2023 Inhibition of gingival fibroblast necroptosis mediated by RIPK3/MLKL attenuates periodontitis. Journal of clinical periodontology 28 37366309
2023 Skp2-mediated MLKL degradation confers cisplatin-resistant in non-small cell lung cancer cells. Communications biology 28 37532777
2020 Cell-specific activation of RIPK1 and MLKL after intracerebral hemorrhage in mice. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 28 33210566
2015 A tale of two domains - a structural perspective of the pseudokinase, MLKL. The FEBS journal 28 26337687
2019 RIP1, RIP3, and MLKL Contribute to Cell Death Caused by Clostridium perfringens Enterotoxin. mBio 27 31848291
2023 PROTACs Targeting MLKL Protect Cells from Necroptosis. Journal of medicinal chemistry 26 37535857
2022 MLKL post-translational modifications: road signs to infection, inflammation and unknown destinations. Cell death and differentiation 26 36175538
2022 Interferon-γ Preferentially Promotes Necroptosis of Lung Epithelial Cells by Upregulating MLKL. Cells 25 35159372
2023 Absence of Either Ripk3 or Mlkl Reduces Incidence of Hepatocellular Carcinoma Independent of Liver Fibrosis. Molecular cancer research : MCR 24 37204757
2022 RIPK3-MLKL signaling activates mitochondrial CaMKII and drives intrarenal extracellular matrix production during CKD. Matrix biology : journal of the International Society for Matrix Biology 24 35964866
2020 RIPK3-MLKL-Mediated Neutrophil Death Requires Concurrent Activation of Fibroblast Activation Protein-α. Journal of immunology (Baltimore, Md. : 1950) 23 32796025
2025 CHMP4C promotes pancreatic cancer progression by inhibiting necroptosis via the RIPK1/RIPK3/MLKL pathway. Journal of advanced research 22 39870301
2024 MLKL-mediated endothelial necroptosis drives vascular damage and mortality in systemic inflammatory response syndrome. Cellular & molecular immunology 22 39349742
2022 The role of MLKL in Hepatic Ischemia-Reperfusion Injury of Alcoholic Steatotic Livers. International journal of biological sciences 22 35173541
2021 MLKL and CaMKII Are Involved in RIPK3-Mediated Smooth Muscle Cell Necroptosis. Cells 22 34572045
2022 NLRC4 Deficiency Leads to Enhanced Phosphorylation of MLKL and Necroptosis. ImmunoHorizons 20 35301258
2022 1,3-Dichloro-2-propanol-Induced Renal Tubular Cell Necroptosis through the ROS/RIPK3/MLKL Pathway. Journal of agricultural and food chemistry 20 36000575
2022 Macrophage Infiltration Initiates RIP3/MLKL-Dependent Necroptosis in Paclitaxel-Induced Neuropathic Pain. Mediators of inflammation 20 36164389
2024 Saracatinib inhibits necroptosis and ameliorates psoriatic inflammation by targeting MLKL. Cell death & disease 19 38331847
2023 GSK840 Alleviates Retinal Neuronal Injury by Inhibiting RIPK3/MLKL-Mediated RGC Necroptosis After Ischemia/Reperfusion. Investigative ophthalmology & visual science 19 38015174
2024 An integrated network pharmacology approach reveals that Ampelopsis grossedentata improves alcoholic liver disease via TLR4/NF-κB/MLKL pathway. Phytomedicine : international journal of phytotherapy and phytopharmacology 18 38981149
2023 MLKL deficiency protects against low-grade, sterile inflammation in aged mice. Cell death and differentiation 18 36755069
2021 Smac mimetics and TRAIL cooperate to induce MLKL-dependent necroptosis in Burkitt's lymphoma cell lines. Neoplasia (New York, N.Y.) 18 33971465
2019 MLKL deficiency inhibits DSS-induced colitis independent of intestinal microbiota. Molecular immunology 18 30738250

Missed literature

Know a paper Affinage missed for MLKL? Flag it for the maintainers and the community.

No submissions yet.